Affymetrix diversifies with $330m eBioscience buy
This article was originally published in Clinica
Executive Summary
Affymetrix, known for its genomic analysis tools for discovery and genetic testing and also as a pioneer gene chip company, has taken another step to diversify and agreed to buy privately-held eBioscience for $330m in cash.